W. Parulekar

发表

Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening

A. Oza, D. Levine, B. Neel, 2019 .

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

P. Murawa, K. Ding, W. Parulekar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

M. Tsao, O. Ludkovski, D. Tu, 2010, Cancer.

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

David Moher, Douglas G Altman, Peter C Gøtzsche, 2013, BMJ.

Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.

W. Parulekar, W. Mendenhall, R. Wong, 2004, International journal of radiation oncology, biology, physics.

Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27.

Bingshu E. Chen, K. Strasser-Weippl, P. Goss, 2016 .

SPIRIT 2013 statement: defining standard protocol items for clinical trials.

D. Rennie, A. Laupacis, D. Moher, 2013, Annals of internal medicine.

Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.

J. Ingle, P. Goss, W. Parulekar, 2008, Journal of the National Cancer Institute.

Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective.

F. Saad, W. Parulekar, R. Meyer, 2011, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.

T. Whelan, M. Levine, W. Parulekar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.

W. Parulekar, J. Pater, 2003, Journal of the National Cancer Institute.

NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.

T. Whelan, W. Parulekar, L. Pierce, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Bingshu E. Chen, M. Parmar, M. Sydes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials

K. Gelmon, L. Seymour, K. Ding, 2022, The oncologist.

Effect of Standard RadiotherapyWith Cisplatin vs Accelerated RadiotherapyWith Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma A Randomized Clinical Trial

Bingshu E. Chen, J. Waldron, B. O'Sullivan, 2017 .

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial

Bingshu E. Chen, J. Waldron, B. O'Sullivan, 2017, JAMA oncology.

The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3

M. Tsao, O. Ludkovski, D. Tu, 2007 .

Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial

Bingshu E. Chen, S. Aparicio, K. Gelmon, 2020, Cancer.

Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial

Bingshu E. Chen, W. Parulekar, Z. Kassam, 2015, Clinical trials.

Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).

M. Sydes, P. Warde, K. Ding, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).

K. Ding, É. Vigneault, W. Parulekar, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, JNCI cancer spectrum.

The effect of metformin vs placebo on sex hormones in CCTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2020, Journal of the National Cancer Institute.

Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).

Bingshu E. Chen, J. Waldron, B. O'Sullivan, 2017, European journal of cancer.

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma-Reply.

Bingshu E. Chen, W. Parulekar, L. Siu, 2017, JAMA oncology.

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

Myles A Brown, A. Oza, D. Levine, 2021, Proceedings of the National Academy of Sciences.

Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic breast cancer (MBC): A biomarker analysis in NCIC CTG MA.31.

S. Aparicio, D. Huntsman, K. Gelmon, 2014 .

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.

P. Austin, D. Tu, W. Parulekar, 2021, European journal of cancer.

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, JAMA.

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.

M. Fehlings, K. Ding, M. Brundage, 2021, The Lancet. Oncology.

Intergroup Randomized Phase 3 Study of Androgen Deprivation Therapy (ADT) plus Radiation Therapy (RT) in Locally Advanced Prostate Cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633)

M. Sydes, P. Warde, K. Ding, 2010 .

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

H. Mackay, E. Eisenhauer, D. Provencher, 2016 .

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer

Bingshu E. Chen, M. Parmar, M. Sydes, 2016, European urology focus.

Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer-Reply.

K. Ding, W. Parulekar, S. Sridhar, 2021, JAMA oncology.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, Journal of the National Cancer Institute.

Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.

T. Whelan, D. Huntsman, W. Parulekar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sentinel lymph node biopsy in early breast cancer: has its time come?

W. Parulekar, J. Pater, 2006, Journal of the National Cancer Institute.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2019, The New England journal of medicine.

Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).

M. Brundage, D. Tu, W. Parulekar, 2009, International journal of radiation oncology, biology, physics.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

D. Tu, W. Parulekar, L. Siu, 2010, Cancer.

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Bingshu E. Chen, S. Leung, T. Nielsen, 2017, JAMA oncology.

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Phase III Clinical Trials with Anticancer Agents

D. Sargent, W. Parulekar, 2011 .

RADICALS-HD: Reflections before the Results are Known.

M. Sydes, Paul Petersen, C. Catton, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

M. Parmar, M. Sydes, F. Saad, 2020, The Lancet.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, The Lancet.

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2015, Journal of the National Cancer Institute.

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

Bingshu E. Chen, T. Whelan, K. Gelmon, 2021, NPJ breast cancer.

Novel endpoints and design of early clinical trials.

E. Eisenhauer, W. Parulekar, E. A. Eisenhauer, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal Strategies for Therapy and Screening

A. Oza, D. Levine, B. Neel, 2021 .

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Donna Niedzwiecki, Edward L Korn, Michael B Atkins, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

Matthew R. Sydes, Gordana Jovic, Bingshu E. Chen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, European urology.

Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

M. Parmar, M. Sydes, C. Parker, 2007, BJU international.

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

I. Tannock, K. Ding, W. Parulekar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

E. Eisenhauer, W. Parulekar, Wendy R Parulekar, 2004, Journal of the National Cancer Institute.

RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).

M. Parmar, M. Sydes, C. Parker, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

M. Buyse, W. Parulekar, P. Roy, 2015, British Journal of Cancer.

Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions.

W. Parulekar, C. Dennie, F. Matzinger, 2001, Chest.

A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3

Albert C. Koong, Dongsheng Tu, Daniel T. Chang, 2016, PloS one.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

T. Whelan, C. Hudis, K. Gelmon, 2016, The New England journal of medicine.

Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).

Bingshu E. Chen, R. Jagsi, T. Whelan, 2019, Journal of Clinical Oncology.

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2015, The New England journal of medicine.

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

T. Whelan, S. Aparicio, D. Huntsman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

D. Tu, W. Parulekar, M. Moore, 2012, European journal of cancer.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

M. Brundage, D. Tu, W. Parulekar, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life

K. Ding, M. Brundage, G. Tienhoven, 2016, Supportive Care in Cancer.

Primary Basaloid Carcinoma of the Nipple with Associated Squamous Cell Carcinoma in Situ

F. O'Malley, W. Parulekar, Chien-Hung Chen, 2009, The breast journal.

Influence of sex on toxicity and treatment outcome in small-cell lung cancer.

F. Shepherd, D. Tu, W. Parulekar, 2005, Journal of Clinical Oncology.

Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium.

M. Gleave, J. Chin, B. Donnelly, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Bingshu E. Chen, T. Whelan, K. Gelmon, 2011, Breast Cancer Research and Treatment.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

T. Whelan, K. Gelmon, J. Ingle, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

SPIRIT 2013 Statement: defining standard protocol items for clinical trials.

David Moher, Douglas G Altman, Peter C Gøtzsche, 2015, Revista panamericana de salud publica = Pan American journal of public health.

Principles of Protocol Development

Bingshu E. Chen, W. Parulekar, A. Sadura, 2019 .

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

S. Aparicio, K. Gelmon, W. Parulekar, 2017, Breast Cancer Research and Treatment.

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Bingshu E. Chen, W. Parulekar, K. Pritchard, 2020, Breast Cancer Research and Treatment.

Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.

J. Waldron, B. O'Sullivan, W. Parulekar, 2021, Oral oncology.

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.

K. Strasser-Weippl, P. Goss, W. Parulekar, 2018, European journal of cancer.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

H. Mackay, E. Eisenhauer, D. Provencher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

Bingshu E. Chen, T. Whelan, K. Gelmon, 2018 .

CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases.

M. Fehlings, K. Ding, M. Brundage, 2020, International journal of radiation oncology, biology, physics.

Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

W. Parulekar, V. Bramwell, K. Pritchard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Bingshu E. Chen, S. Aparicio, A. Richardson, 2017 .

Re: Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

M. Sydes, W. Parulekar, M. Mason, 2015 .

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]

M. Sydes, F. Saad, C. Parker, 2019, Annals of Oncology.

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

F. Saad, C. Catton, K. Ding, 2008, Current oncology.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

M. Stockler, W. Parulekar, M. Frydenberg, 2023, The Lancet. Oncology.

– Prostate Cancer Estimating the Impact of Randomised Control Trial Results on Clinical Practice : Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer

Bingshu E. Chen, M. Parmar, M. Sydes, 2016 .

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

J. Ingle, W. Parulekar, 2016, The New England journal of medicine.

Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report

Susan M. Chang, P. Gerszten, M. Bilsky, 2018, Neuro-oncology.

Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, Cancer Research.

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.

M. Stockler, K. Ding, W. Parulekar, 2020, JAMA oncology.

Development and validation of a nomogram to predict lymphedema following axillary surgery and radiotherapy in women with breast cancer from the NCIC CTG MA.20 randomized trial.

Bingshu E. Chen, A. Rademaker, T. Whelan, 2019, International journal of radiation oncology, biology, physics.

Randomized, D ouble-Blind, C ontrolled T rial o f M itoxantrone/ Prednisone a nd C lodronate V ersus M itoxantrone/Pre dnisone and P lacebo i n P atients W ith H ormone-Refracto ry P rostate Cancer a nd P ain

K. Ding, W. Parulekar, K. Chi, 2003 .

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Final Analysis of Intergroup Randomized Phase III Study of Androgen Deprivation Therapy (ADT) ± Radiation Therapy (RT) in Locally Advanced Prostate Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633)

Bingshu E. Chen, M. Sydes, P. Warde, 2012 .

Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110).

Bingshu E. Chen, M. Parmar, M. Sydes, 2012 .

Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R

J. Ingle, P. Goss, D. Tu, 2021, Breast Cancer Research and Treatment.

Mature Local Control and Reirradiation Rates Comparing Spine Stereotactic Body Radiotherapy to Conventional Palliative External Beam Radiotherapy.

W. Parulekar, M. Ruschin, A. Sahgal, 2022, International journal of radiation oncology, biology, physics.

Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study.

M. Parmar, M. Sydes, R. Cowan, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).

A. Wyatt, K. Ding, M. Brundage, 2022, Journal of Clinical Oncology.

Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC).

F. Shepherd, D. Tu, W. Parulekar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive model for survival in patients having repeat radiation treatment for painful bone metastases.

K. Ding, M. Brundage, W. Parulekar, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

E. Winer, T. Whelan, C. Hudis, 2016 .

Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).

Bingshu E. Chen, T. Whelan, K. Gelmon, 2013 .

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, Lancet.

Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment.

W. Parulekar, W. Hopman, A. Alfakeeh, 2015, Japanese journal of clinical oncology.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, Lancet.

A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.

A. Koong, G. Heestand, D. Tu, 2014 .

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

T. Whelan, M. Brundage, J. Ingle, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

T. Whelan, S. Aparicio, K. Gelmon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience.

D. Tu, W. Parulekar, K. Pritchard, 2006, Journal of Clinical Oncology.

A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell

J. Machiels, K. Sultanem, W. Parulekar, 2018, Annals of Oncology.

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

D. Tu, W. Parulekar, M. Moore, 2012, European journal of cancer.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

W. Parulekar, H. Au, D. Walde, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32

Bingshu E. Chen, T. Whelan, K. Gelmon, 2017, Breast Cancer Research and Treatment.

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Bingshu E. Chen, T. Whelan, K. Gelmon, 2023, Breast Cancer Research and Treatment.

LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)

M. Parmar, M. Sydes, C. Parker, 2022, Annals of Oncology.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer

Bingshu E. Chen, K. Gelmon, W. Parulekar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.